Aging of the Human Neuromuscular System: Clinical Considerations

Muscle Aging, Inclusion-Body Myositis and Myopathies

Volumn , Issue , 2011, Pages 33-54

  Engel, W King ^a   Askanas, Valerie ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

"Pseudo ALS"; Aging era; Diabetic neuropathy; Human neuromuscular system; Therapeutic principles; XMRV retrovirus

Indexed keywords

EID: 84885570707     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444398311.ch2     Document Type: Chapter

References (75)

1. Engel WK, Prentice AF. (1993) Some polyneuropathies (PNs) in insulin-requiring adult-onset diabetes (IRAOD) can benefit remarkably from anti-dysimmune treatments. Neurology 43, 255-256.
2. Engel, WK. (2002) In type-2 diabetes, diabetic neuropathy is usually responsive to intravenous IgG (IVIG) treatment, ergo presumably dysimmune. Acta Myologica 21, A79.
3. Engel WK. (1997) Intravenous immunoglobulin (IVIG) - an often-overlooked treatment - produces rapid, remarkable, sustained benefit in "diabetic neuropathy complex", suggesting a dysimmune mechanism. Ann Neurol 42, 414.
4. Engel WK. (2003) Intravenous immunoglobulin G is remarkably beneficial in chronic immune dysschwannian/ dysneuronal polyneuropathy, diabetes-2 neuropathy, and potentially in severe acute respiratory syndrome. Acta Myologica 22, 97-103.
5. Engel WK. (2006) "Pseudo-lupus", benign neutropenia, and other probable non-worrisome blood-component changes due to IVIG treatment. Neuromuscul Disord 16, 647-648.
6. Engel WK. (2006) Longer-term (>3 months), IVIG treatment to optimize clinical benefit and cellular protection usually requires an individualized adjustable schedule - not fixed regimentation. Neuromuscul Disord 16, 703-704.
7. Engel WK. (2009) Intravenous immunoglobulin in relapsing-remittin multiple sclerosis: a dose-finding trial. Neurology 73, 1077-1078.
8. Engel WK. (2010) Multi-microcramps (MMC) syndrome: a new pathogenic concept of subtle lower motor-neuron (LMN) lability causing very disturbing, continuing muscle pains, sometimes gratifying treatable - but often misinterpreted as mysterious "fibromyalgia" or "psychogenic". Neurology 74, A465.
9. Mahajan S, Engel WK. (2010) Symptomatic treatment for muscle cramps (an evidence-based review). Letter to the Editor. Neurology 75, 1397-1398.
10. Engel WK, Warmolts JR. (1971) Myasthenia gravis: a new hypothesis of the pathogenesis and a new form of treatment. Ann N Y Acad Sci 183, 72-87.
11. Warmolts JR, Engel WK. (1972) Benefit from alternate- day prednisone in myasthenia gravis. NEngl J Med 286, 17-20.
12. Warmolts JR, Engel WK, Whitaker JN. (1970) Alternate- day prednisone in a patient with myasthenia gravis. Lancet 2, 1198-1199.
13. Engel WK. (1976) Myasthenia gravis, corticosteroids, anticholinesterases. Ann NY Acad Sci 274, 623-630.
14. Engel WK. (2001) Polyneuropathy in type 2 diabetes mellitus. Lancet 358, 2086.
15. Engel WK. (1991) RNA metabolism in relation to amyotrophic lateral sclerosis. Adv Neurol 56, 125-153.
16. Engel WK. (1991) Does a retrovirus cause amyotrophic lateral sclerosis?. Ann Neurol 30, 431-433.
17. Engel WK, Kurland LT, Klatzo I. (1959) An inherited disease similar to amyotrophic lateral sclerosis with a pattern of posterior column involvement. An intermediate form? Brain 82, 203-220.
18. Engel WK. (2008) In ALS, viral-dysmetabolic mechanisms acting via neuronal-nurturing cells (NNCs) could portend replacement therapy and should be sought by multi-tissue screening for rev-transcriptase (RT) and viral tracks. Neuromuscul Disord 18, 764.
19. McCormick AL, Brown RH, Cudkowicz ME et al. (2008) Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology 70: 278-283.
20. Engel WK, Patterson JM, Tauzin MR et al. (1988) Liver-biopsy abnormalities in amyotropic lateral sclerosis. Ann Neurol 24, 163.
21. Prentice A, Engel WK, Rasheed S. (1992) Amyotrophic lateral sclerosis (ALS) associated with HTLV-I infection. Neurology 42, 454-455.
22. Engel WK. (1989) High-dose TRH treatment of neuromuscular diseases: summary of Mechanisms and critique of clinical studies. Ann NY Acad Sci 553, 462-472.
23. Engel WK, Siddique T, Nicoloff JT. (1983) Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet 2, 73-75.
24. Engel WK, Beydoun SR. (1985) Myophosphorylase deficiency (MPD) probably also involves lower motor neurons (LMNs) in some cases. Neurology 35, 304.
25. Engel WK. (1977) Introduction to disorders of the motor neuron, nerves and related abnormalities. In: Goldensohn ES, Appel SH (eds), Scientific Approaches to Clinical Neurology. Lea Febiger, Philadelphia, pp. 1250-1321.
26. Yan J, Deng HX, Siddique N et al. (2010) Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75, 807-814.
27. Engel WK, Hopkins LC, Rosenberg BJ. (1985) Fasciculating progressive muscular atrophy (F-PMA) remarkably responsive to anti-dysimmune treatment (ADIT)-a possible clue to more ordinary ALS?. Neurology 35, 72.
28. Engel WK. (1995) Rapid and continued improvement from intravenous immunoglobulin treatment of asymmetrical chronic progressive muscular atrophy after 19 years of disease progression. Ann Neurol 38, 333-334.
29. Adornato BT, Engel WK, Kucera J et al. (1978) Benign focal amyotrophy. Neurology 28, 399.
30. Engel WK, Askanas V. (2006) Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology 66, S20-29.
31. Askanas V, Engel WK, Alvarez RB. (1993) Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 43, 1265-1267.
32. Kula RW, Engel WK, Line BR. (1977) Scanning for soft-tissue amyloid. Lancet 1, 92-93.
33. Engel WK, Trotter JL. (1979) Plasma-cell dyscrasic amyloid neuropathy: a parasparafucile phenomenon?. In: Serratrice G, Roux H (eds), Peroneal Atrophies and Related Disorders. Masson Publishing Co, New York, pp. 339-347.
34. Patten BM, Bilezikian JP, Mallette LE et al. (1973) Neuromuscular disease in primary hyperparathyroidism. Ann Intern Med 80, 182-193.
35. Engel WK. (1987) A simple, low-tech clinical test and treatment for cervical root compression. Ann Neurol 22, 165.
36. Engel WK. (1978) Ponderous-purse disease. Letter to the Editor. New Engl J Med 299, 557.
37. Whitaker JN, Engel WK. (1972) Vascular deposits of immunoglobin and complement in idiopathic inflammatory myopathy. New Engl J Med 286, 333-338.
38. Whitaker JN, EngelWK. (1973) Mechanisms of muscle injury in idiopathic inflammatory myopathy. New Engl J Med 289, 107-108.
39. Mendell JR, Engel WK, Derrer EC. (1970) Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 172, 1143-1145.
40. Mendell JR, Engel WK, Derrer EC. (1972) Increased plasma enzyme concentrations in rats with functional ischemia of muscle provide a possible model of Duchenne muscular dystrophy. Nature 239, 522-524.
41. Engel WK. (1973) Duchenne muscular dystrophy: a histologically based ischemia hypothesis and comparison with experimental ischemia myopathy. In: Pearson CM, Mostofi FK (eds), The Striated Muscle. Williams&Wilkins Co, Baltimore, vol. 12, pp. 453-472.
42. Engel WK. (1977) Integrative histochemical approach to the defect of Duchenne muscular dystrophy. In: Rowland LP (ed.), Pathogenesis of the Human Muscular Dystrophies, American Elsevier Publishing Co, New York, Excerpta Medica, pp. 277-309.
43. Engel WK, Derrer EC. (1975) Drugs blocking the muscle-damaging effects of 5-HT and nonadrenaline in aorta-ligated rats. Nature 254, 151-152.
44. Kyle RA. (1978) Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 64, 814-826.
45. Adornato BT, Engel WK. (1977) MB-creatine phosphokinase isoenzyme elevation not diagnostic of myocardial infarction. Arch Intern Med 137, 1089-1090.
46. Warmolts JR, EngelWK. (1973) Correlation ofmotor unit behavior with histochemical and myofiber type in humans by open-biopsy electromyography. In: Desmedt JE (ed.), New Developments in Electromyography and Clinical Neurophysiology, Karger, Basel, pp. 35-40.
47. Warmolts JR, Engel WK. (1972) Open biopsy electromyography. I. Correlation of motor unit behavior with histochemical muscle fiber type inhumanlimb muscle. Arch Neurol 27, 512-517.
48. Engel WK. (1977) Introduction to the myopathies. In: Goldensohn ES, Appel SH (eds), Scientific Approaches to Clinical Neurology, Lea Febiger, Philadelphia, pp. 1602-1632.
49. Engel WK. (1973) "Myopathic EMG" -nonesuch animal. New Engl J Med 289, 485-486.
50. Engel WK. (1975) Brief, small, abundant motor-unit action potentials. Neurology 25, 173-176.
51. Karpati G, EngelWK. (1968) Correlative histochemical study of skeletal muscle after a suprasegmental denervation, peripheral nerve section, and skeletal fixation. Neurology 18, 681-692.
52. Karpati G, Engel WK. (1968) Histochemical investigation of fiber type ratios with the myofibrillar ATPase reaction in normal and denervated skeletal muscles in guinea pig. Am J Anat 122, 145-155.
53. Resnick JS, Engel WK, Griggs RC et al. (1968) Acetazolamide prophylaxis in hypokalemic periodic paralysis. N Engl J Med 278, 582-586.
54. Griggs RC, Engel WK, Resnick JS. (1970) Acetazolamide treatment of hypokalemic periodic paralysis. Ann Intern Med 73, 39-48.
55. Dalakas MC, Engel WK. (1983) Treatment of "permanent" muscle weakness in familial hypokalemic periodic paralysis. Muscle Nerve 6, 182-186.
56. Askanas V, Engel WK. (2003) Toxicity of long-chain fatty acids (LCFAs) in muscle carnitine deficiency and other LCFA endodissolutions? Dietary LCFA restriction associated with dramatic long-term improvement. Neurology 36, 94.
57. Engel, WK. (1986) Toxic role of long-chain fattyacids in muscle carnitine deficiency and other LCFA endodissolutions: dietary LCFA retriction associated with dramatic long-term improvement. Neurology 36 (Suppl 1), 94.
58. Askanas V, Engel WK, Kwan HH et al. (1985) Autosomal dominant syndrome of lipid neuromyopathy with normal carnitine: successful treatment with long-chain fatty-acid-free diet. Neurology 35, 66-72.
59. Prockop LD, Engel WK, Shug AL. (1983) Nearly fatal muscle carnitine deficiency with full recovery after replacement therapy. Neurology 33, 1629-1631.
60. Engel WK, Hanna CJ, Misra AK. (1990) HTLV-I-associated myelopathy. New Engl J Med 323, 552.
61. Engel WK, Misra AK, Alexander SJ et al. (1990) Syndrome of continuous motor unit activity responsible to immunosuppression suggests dysimmune pathogenesis. Neurology 40, 118.
62. DeVivo DC, Engel WK. (1970) Remarkable recovery of a steroid-responsive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry 33, 62-69.
63. EngelWK, Borenstein A, DeVivoDCet al. (1972) Highsingle-dose alternate-day prednisone (HSDAD-PRED) in the treatment of dermatomyositis/polymyositis complex. Trans Am Neurol Assn 97, 272-275.
64. Engel WK, Resnick JS. (1966) Late-onset rod myopathy -a newly recognized, aquired and progressive disease. Neurology 16, 308-309.
65. Engel WK. (2007) Late-onset rod myopathy with monoclonal immunoglobulin can be treatable with IVIG. Neuromuscul Disord 17, 885.
66. Engel WK. (1977) Rod (nemaline) disease. In: Goldensohn ES, Appel SH (eds), Scientific Approaches to Clinical Neurology, Lea Febiger, Philadelphia, pp. 1667-1691.
67. Mahajan S, Engel WK, Luthra I, Gupta V. (2011) Adult-onset rod myopathy syndrome (AORMS): sustained benefit from IVIG plus rituximab. Ann Neurol, in press.
68. Engel WK, Lichter AS, Galdi AP. (1982) Polymyositis: remarkable response to total body irradiation. Lancet 1, 658.
69. Engel WK, Cuneo RA, Levy HB. (1978) Polyinosinicpolycytidylic acid treatment of neuropathy. Lancet 1, 503-504.
70. Engel WK, Adornato B. (1993) Fever-responsive neuropathy (FRN) benefited by long-term interferon alpha-2A (Ib) treatment. Can J Neurol Sci 4, S44.
71. Engel WK. (2007) Fever-responsive dysschwannian neuropathy (FRDN): Interferon-alpha 2a (Ia) treatment has produced remarkable recovery from total quadriplegia, the benefit now persisting 4 years beyond the 14 years of therapy. Neuromuscul Disord 17, 885.
72. Engel WK. (2011) Remarkable benefit persisting undiminished for 8 years after stopping 14 years of In-terferon-a 2A (Inf-a) treatment for fever-responsive dysimmune neuropathy (FRDN): possibly a combined antidysimmune plus antiviral effect, and thus a putative model for future "combined antidysimmune" therapies. Neurology 76, A520.
73. Engel WK, Askanas V. (1976) Letter: overlooked avian oncornavirus in cultured muscle-functionally significant?. Science 192, 1252-1253.
74. Engel, WK (1969) Motor neuron histochemistry in ALS and infantile spind muscular a trophy. In Norr is FH Jr., Kurland LT (eds) Motor Neuron Diseases, pp 218-234. Grune & Stratton, New York.
75. Renton AE, Majounie E, Waite A, et. al. (2011) A hexanucleotide repeat expansion in C90RF72 is the cause of chromosome 9p 21-linke ALS-FTD. Neuron DOI: 10.10.16, neuron. 2011.09.010.